PATIENT CHARACTERISTICS AND TREATMENT PATTERNS IN CHRONIC HEART FAILURE- RESULTS FROM A MULTINATIONAL REAL-WORLD CROSS SECTIONAL SURVEY
Author(s)
Proenca CC1, Viriato D2, Lahoz R3, Agrawal R4, Cotton S5, Jackson J5, Calado F3
1Wellmera AG, Basel, Switzerland, 2Novartis Farma – Produtos Farmacêuticos S.A., Porto Salvo, Portugal, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Healthcare Pvt. Ltd., Hyderabad, India, 5Adelphi Real World, Bollington, Macclesfield, UK
OBJECTIVES: To understand the patient characteristics and treatment patterns of chronic heart failure (CHF) patients in a real-world setting. METHODS: A cross-sectional survey was conducted and patient record forms were completed by 563 cardiologists for 4903 CHF patients. Treatment patterns for the following drug classes were described: angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor II blocker (ARB), beta blocker (BB), and mineralocorticoid receptor antagonist (MRA). Pooled data for 10 countries (Argentina, Brazil, China, Colombia, France, Japan, Mexico, Russia, Saudi Arabia and Turkey) is presented. RESULTS: The mean (SD) age of a CHF patient was 67.2 (12.5) years with a male predominance (57%). Mean age ranged from 58.1 (7.8) years in Saudi Arabia to 72.8 (13.3) years in Japan and male percentage from 51% (Turkey) to 69% (Saudi Arabia). Overall, 28% patients had HFrEF [LVEF<40%, inter-country range: 11% (Brazil)-57% (Turkey)], 42% had HFpEF [LVEF≥50%, 3% (Turkey)-53% (Brazil)]. The mean number of comorbidities was 3.5 (2.3); the most frequent two were hypertension (70%) and hyperlipidemia (34%). Three quarters of patients were classified as having mild symptoms (NYHA class I: 26%, NYHA II: 49%); 21% and 4% patients were NYHA III and IV, respectively. The most common treatment combination were ACEi/ARB+BB [41%, inter-country range: 25% (Russia)-53% (Saudi)], ACEi/ARB+BB+MRA [25%, 10% (Turkey)-47% (Russia)] and ACEi/ARB [16%, 4% (Saudi)-24% (Russia)] for the overall CHF population. Patients with HFrEF were most frequently prescribed ACEi/ARB+BB+MRA [40%, 8% (Turkey)-68% (Argentina)] followed by ACEi/ARB+BB [31%, 13% (Russia)-50% (Turkey)] and ACEi/ARB [10%, 1% (Argentina)-24% (Russia)]. Whereas, the most common treatment combination for HFpEF patients was ACEi/ARB+BB [48%, 37% (Japan)-68% (Saudi)] followed by ACEi/ARB+BB+MRA [18%, 7% (Colombia)-41% (Russia)] and ACEi/ARB [18%, 9% (Saudi)-31% (Brazil)]. CONCLUSIONS: The two most frequent treatment combinations were ACEi/ARB+BB with or without MRA and the distribution across countries was heterogeneous.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PCV169
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Treatment Patterns and Guidelines
Disease
Cardiovascular Disorders